Not available
Quote | AtriCure Inc. (NASDAQ:ATRC)
Last: | $23.53 |
---|---|
Change Percent: | 0.67% |
Open: | $23.83 |
Close: | $23.53 |
High: | $25.14 |
Low: | $23.49 |
Volume: | 932,495 |
Last Trade Date Time: | 07/25/2024 03:00:00 am |
News | AtriCure Inc. (NASDAQ:ATRC)
2024-07-25 08:51:50 ET Summary AtriCure, Inc. is a market leader in surgical solutions for atrial fibrillation, LAA management, and post-operative pain management, serving 2,000 hospitals globally. AtriCure's latest project involves expanding into the European market with innovati...
2024-07-23 09:47:32 ET More on AtriCure AtriCure Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial information for AtriCure Read the full article on Seeking Alpha For furth...
Message Board Posts | AtriCure Inc. (NASDAQ:ATRC)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ATRC News Article - AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare | whytestocks | investorshangout | 02/17/2023 1:40:52 PM |
whytestocks: $ATRC News Article - AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare | whytestocks | investorshangout | 12/20/2022 4:50:46 PM |
whytestocks: $ATRC News Article - AtriCure Reports Preliminary Results for Fourth Quarter and Full Y | whytestocks | investorshangout | 01/10/2022 5:45:48 PM |
whytestocks: $ATRC News Article - AtriCure, inc (ATRC) Q3 2021 Earnings Call Transcript | whytestocks | investorshangout | 11/04/2021 5:30:52 PM |
whytestocks: $ATRC News Article - AtriCure's EPi-Sense System Approved by FDA for Treatment of Long- | whytestocks | investorshangout | 04/29/2021 12:35:51 PM |
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...